Genomic medicine startup Lucence and the Agency for Science, Technology and Research (A*STAR), Singapore’s national research agency and a statutory board under the Ministry of Trade and Industry, today announced study results indicating that the reagent used in Lucence’s SAFER Sample saliva collection kit inactivates SARS-CoV-2 within 45 seconds of sample collection.
The development of the SAFER...
Genomic medicine startup Lucence announced that the development of the SAFER-Sample (Stabilization of nucleic Acid Formulation for Evaluation of RNA) kit, a sample collection medical device to facilitate more accessible testing of viral infections such as COVID-19.
WHY IT MATTERS
Currently, definitive diagnosis of RNA viral infections such as COVID-19 requires patients with respiratory infections...
“What we have tracked and seen in the last four years is a very vibrant ecosystem, which was in the past, very e-commerce health focused to nowadays, very sophisticated with AI drug discovery, clinical trials and digital therapeutics etc. In 2018, the total amount of venture capital that was invested in Asia Pacific amounted to about $6.8B. To put in context, in the US it is $8.2B and $2B for...
Singapore-headquartered genomic medicine startup Lucence announced it has raised $20 million in Series A funding. The round was led by IHH Healthcare, one of the world’s largest integrated private healthcare groups, with 80 hospitals in 10 countries worldwide. Other participants include SGInnovate, existing investors Heliconia Capital, a subsidiary of Temasek Holdings, Lim Kaling and Koh Boon...
